A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
- Conditions
- Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerOvarian Cancer
- Interventions
- Registration Number
- NCT02631876
- Lead Sponsor
- ImmunoGen, Inc.
- Brief Summary
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
- Detailed Description
Participants will be randomized to either mirvetuximab soravtansine or investigator's choice chemotherapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 366
- Participants must be diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
- Participants must have folate receptor alpha positive tumor expression as defined in the protocol
- Participants must have platinum-resistant ovarian cancer, defined as progression within 6 months from completion of a minimum of four cycles of platinum-containing therapy.
- Participants must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy is appropriate as the next line of treatment
- Participants must have at least one lesion that meets the definition of measurable disease by RECIST 1.1
- Diagnosis of clear cell, low grade ovarian cancer or mixed tumors
- Participants with primary platinum-refractory disease
- Serious concurrent illness or clinically relevant active infection as defined in the protocol
- Prior treatment with mirvetuximab soravtansine
- Women who are pregnant or breast feeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Investigator's Choice (IC) Chemotherapy Pegylated liposomal doxorubicin Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m\^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks) Investigator's Choice (IC) Chemotherapy Paclitaxel Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m\^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks) Investigator's Choice (IC) Chemotherapy Topotecan Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m\^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks) Mirvetuximab Soravtansine Mirvetuximab soravtansine Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee \[BIRC\]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm) PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining) From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm) PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by BIRC Per RECIST1.1 From randomization until first BOR of CR or PR (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm) ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the SoD of target lesions, taking as reference the baseline SoD.
Overall Survival (OS) From the date of randomization until the time of death (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm) OS was defined as the time from the date of randomization until the date of death from any cause. Participants who did not experience the event of death were censored at their last date known to be alive. OS was estimated using the Kaplan-Meier method.
Number of Participants Achieving at Least a 15% (≥ 15-Point) Absolute Improvement From Baseline on the EORTC QLQ-OV28 Abdominal/Gastrointestinal (AB/GI) Symptom Subscale at Week 8/9 Assessment Baseline, Week 8/9 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer 28 (EORTC QLQ-OV28) is a 28-item ovarian cancer supplemental module. It comprises of 6 symptom scales (AB/GI symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal symptoms, body image, attitude to disease, treatment), and sexual functioning. Participants were asked to indicate extent to which they experienced AB/GI symptoms. Participants responded on a scale of 1-4(1=not at all, 2=a little, 3=quite a bit, 4=very much) to following: Did you have abdominal pain? Did you have a bloated feeling in your abdomen? Did you have problems with your clothes feeling too tight? Did you experience any change in bowel habit as a result of your disease or treatment? Were you troubled by passing wind/gas/flatulence? Have you felt full too quickly after beginning to eat? Have you had indigestion/heartburn? Data were transformed to a scale from 0-100. Lower scores=better health.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm) Adverse event (AE): any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Severity: graded per National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v4.03 on following scale: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Relation of AE to treatment was determined by investigator. Serious AEs: death, life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent/significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs: any AE that emerged on or after the first dose, and within 30 days of the last dose. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported AEs module.
Gynecologic Cancer Intergroup (GCIG) CA-125 Response Rate: Percentage of Participants With GCIG CA-125 Confirmed Clinical Responses From first dose of study drug until CA-125 response (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm) CA-125 Response rate wasdefined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100.
PFS, as Assessed by Investigator Per RECIST Version 1.1 From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm) PFS was defined as the time from randomization until PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Duration of Response (DOR), as Assessed by BIRC Per RECIST v1.1 From the date of first response (CR or PR) until the date of PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm) DOR was defined as the time from the date of the first response (CR or PR), whichever was recorded first, until the date of PD. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was only defined for participants who had a BOR of CR or PR using the method of Kaplan-Meier.
Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of Mirvetuximab Soravtansine,Total M9346A Antibody, DM4, and S-methyl DM4 Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1 and 3; and Day 8 and 15 of Cycles 1 and 3 PK parameters were calculated using standard non-compartmental methods.
Number of Participants With Anti-Drug Antibodies (ADA) Pre-dose and within 5 minutes after mirvetuximab soravtansine infusion on Day 1 of Cycles 1, 2, and 4; pre-dose on Day 1 of Cycle 6 An electrochemiluminescent method was used for the detection of anti-mirvetuximab soravtansine antibodies in plasma from samples collected in dipotassium ethylenediaminetetraacetic acid (K2EDTA) tubes. The qualitative assay was designed to detect anti-mirvetuximab soravtansine antibodies in human plasma.
Trial Locations
- Locations (131)
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center
🇺🇸Augusta, Georgia, United States
UCLA Women's Health Clinical Research Unit - OBGYN
🇺🇸Los Angeles, California, United States
Hillcrest Hospital
🇺🇸Mayfield, Ohio, United States
AZ Groeninge - Oncology Centre
🇧🇪Kortrijk, Belgium
Centre Hospitalier de l'Ardenne
🇧🇪Libramont, Belgium
Arizona Oncology Associates, PC - HOPE
🇺🇸Tucson, Arizona, United States
Texas Oncology - The Woodlands, Gynecologic Oncology
🇺🇸The Woodlands, Texas, United States
Texas Oncology-Austin Central
🇺🇸Austin, Texas, United States
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Arizona Oncology Associates, PC - HAL
🇺🇸Tempe, Arizona, United States
Norwalk Hospital/WCHN
🇺🇸Norwalk, Connecticut, United States
MD Anderson Cancer Center - Cooper Health
🇺🇸Camden, New Jersey, United States
WK Physician Network Clinical Research
🇺🇸Shreveport, Louisiana, United States
Overlook Medical Center
🇺🇸Summit, New Jersey, United States
Oklahoma Cancer Specialists and Research Institute, LLC
🇺🇸Tulsa, Oklahoma, United States
Women & Infants of Rhode Island
🇺🇸Providence, Rhode Island, United States
University of Massachusetts Memorial Medical Center
🇺🇸Worcester, Massachusetts, United States
Levine Cancer Institute - Carolinas Medical Center
🇺🇸Charlotte, North Carolina, United States
Texas Oncology - Fort Worth
🇺🇸Fort Worth, Texas, United States
Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
Memorial Sloan Kettering Cancer Center and (MSK Monmouth) and ( MSK Westchester)
🇺🇸New York, New York, United States
Onkologicke oddeleni Krajske nemocnice T. Bati, a.s., Zlin
🇨🇿Zlín, Czechia
CHRU Jean Minjoz
🇫🇷Besançon, France
Magee - Womens Hospital of UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
Bon Secours Hospital
🇮🇪Cork, Ireland
Universitaire Ziekenhuizen (UZ) Leuven-Gasthuisberg
🇧🇪Leuven, Belgium
Kadlec Clinic Hematology & Oncology
🇺🇸Kennewick, Washington, United States
Institut de Cancerologie de L'Ouest - site Paul Papin
🇫🇷Angers, France
Hollings Cancer Center
🇺🇸Charleston, South Carolina, United States
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Italy
Centre Hospitalier Lyon-Sud
🇫🇷Pierre-Bénite, France
Gustave Roussy Institution
🇫🇷Villejuif, France
Romagnolo per lo Studio e la Cura dei Tumori IRST-IRCCS - Oncologia medica
🇮🇹Meldola (FC), Italy
Cochin Hospital
🇫🇷Paris, France
Hôpital Croix St-Simon
🇫🇷Paris, France
Fondazione IRCCS National Cancer Institute
🇮🇹Milan, Italy
Istituto Nazionale Tumori- G. Pascale
🇮🇹Naples, Italy
LLC "VitaMed"
🇷🇺Moscow, Russian Federation
Centre hospitalier de l'Université de Montréal
🇨🇦Montreal, Quebec, Canada
University Hospital Ostrava
🇨🇿Ostrava Poruba, Czechia
Porodnicka A Gynekologicka Klinika
🇨🇿Hradec Králové, Czechia
State Budget Institution of Health "Leningrad Regional Oncologicacal Dispensary"
🇷🇺Saint Petersburg, Russian Federation
Hospital Universitario Ramon Y Cajal
🇪🇸Madrid, Spain
Hopital de la CitedelaSante
🇨🇦Laval, Quebec, Canada
Institut Català d'Oncologia - Unitad de Investigación Clínica
🇪🇸Barcelona, Spain
Azienda Sanitaria Locale (ASL)
🇮🇹Brindisi, Italy
Oncology and Radiology Institute Serbia
🇷🇸Belgrade, Serbia
Ospedale San Raffaele
🇮🇹Milan, Italy
ICO Hospital Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
IOR - Hospital Quiron Dexeus
🇪🇸Barcelona, Spain
Hospital Vall D'Hebron
🇪🇸Barcelona, Spain
Institut de Cancerologie de Lorraine
🇫🇷Vandœuvre-lès-Nancy, France
Mater Private Hospital and Mater Misericordiae University Hospital
🇮🇪Dublin, Ireland
Oncology Institute Vojvodina
🇷🇸Sremska Kamenica, Serbia
Hospital Universitario Gregorio Maranon
🇪🇸Madrid, Spain
Istituto Europeo di Oncologia
🇮🇹Milano, MI, Italy
Azienda Unita Sanitaria Locale di Ravenna
🇮🇹Faenza, Italy
Institut Curie-Hopital Rene Huguenin
🇫🇷Saint-Cloud, France
Hospital Reina Sofia
🇪🇸Córdoba, Spain
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
Holy Cross Hospital
🇺🇸Silver Spring, Maryland, United States
University Clinical Center of Republic of Srpska
🇧🇦Banja Luka, Bosnia and Herzegovina
Onkologikoa
🇪🇸Donostia San Sebastian, Gipuzkoa, Spain
Hopitaux Universitaires de Geneve
🇨🇭Geneve, Switzerland
UCL Cancer Institute
🇬🇧London, England, United Kingdom
Ochsner Clinic Foundation
🇺🇸New Orleans, Louisiana, United States
Dartmouth-Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Community Health Network, Inc.
🇺🇸Indianapolis, Indiana, United States
Indiana University School of Medicine
🇺🇸Indianapolis, Indiana, United States
University of California San Diego Medical Center
🇺🇸San Diego, California, United States
California Pacific Medical Center
🇺🇸San Francisco, California, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
University of Cincinnati Medical Center
🇺🇸Cincinnati, Ohio, United States
University of Oklahoma Health Sciences Center
🇺🇸Oklahoma City, Oklahoma, United States
Froedtert and Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
McGill University Health Centre - Glen Site
🇨🇦Montréal, Quebec, Canada
Kaiser Permanente Medical Center
🇺🇸Vallejo, California, United States
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
Florida State University College of Medicine
🇺🇸Sarasota, Florida, United States
Norton Cancer Institute
🇺🇸Louisville, Kentucky, United States
Sudarshan Sharma LTD
🇺🇸Hinsdale, Illinois, United States
Women's Cancer Care
🇺🇸Covington, Louisiana, United States
Mercy Women's Oncology
🇺🇸Springfield, Missouri, United States
Center of Hope
🇺🇸Reno, Nevada, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
🇺🇸New York, New York, United States
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
University of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
London Health Sciences Centre
🇨🇦London, Ontario, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Sunnybrook Research Institute - Odette Cancer Centre
🇨🇦Toronto, Ontario, Canada
Centre Eugene Marquis
🇫🇷Rennes, France
Centre Armoricain de radiotherapie, Imagerie Medicale et Oncol
🇫🇷Plérin, France
Institut Bergonie
🇫🇷Bordeaux, France
MD Anderson Cancer Center - Madrid
🇪🇸Madrid, Spain
Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
🇮🇹Bologna, Italy
Institut Claudius Regaud
🇫🇷Toulouse, France
Clinical Centre Nis, Oncology Clinic
🇷🇸Niš, Serbia
State Budget-Funded Healthcare Institution of Novosibirsk Oblast "Novosibirsk Oblast Oncology Dispensary"
🇷🇺Novosibirsk, Russian Federation
Hospital Teresa Herrera (CHUACoruña)
🇪🇸A Coruña, Spain
Servicio de Oncología Médica Hospital Universitario La Paz
🇪🇸Madrid, Spain
Complejo Hospitalario Granada
🇪🇸Granada, Spain
Hospital Son Llatzer (HSLL)
🇪🇸Palma de Mallorca, Spain
Hospital Universitario HM Sanchinarro
🇪🇸Madrid, Spain
Hospital Regional Universitario Malaga - Hospital Materno Infantil de Málaga
🇪🇸Malaga, Spain
Instituto Valenciano de Oncologia
🇪🇸Valencia, Spain
Kantonsspital
🇨🇭Winterthur, Zurich, Switzerland
Kantonsspital Winterthur, Medizinische Onkologie
🇨🇭Winterthur, Zurich, Switzerland
Nottingham University Hospitals NHS Trust - City Hospital
🇬🇧Nottingham, England, United Kingdom
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH)
🇬🇧Sutton, England, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, England, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust - Royal Preston Hospital
🇬🇧Preston, England, United Kingdom
The Royal Wolverhampton Hospitals NHS Trust - New Cross Hospital - GOW
🇬🇧Wolverhampton, England, United Kingdom
Peterborough City Hospital
🇬🇧Peterborough, Great Britain, United Kingdom
Mount Vernon Cancer Centre
🇬🇧Northwood, United Kingdom
Cancer,Haematology and Physics Directorate, Cancer Centre Royal Stoke University
🇬🇧Stoke-on-Trent, Staffordshire, United Kingdom
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, Scotland, United Kingdom
University Hospitals Coventry & Warwickshire NHS Trust, Arden Cancer Centre
🇬🇧Coventry, United Kingdom
OSU Wexner Medical Center
🇺🇸Columbus, Ohio, United States
The University of New Mexico Comprehensive Cancer Center - Memorial Medical Center
🇺🇸Albuquerque, New Mexico, United States
Fairview Hospital, Moll Pavilion Cancer Center
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Texas Oncology-Tyler
🇺🇸Tyler, Texas, United States
Budget-Funded Healthcare Institution of Omsk Oblast "Clinical Oncology Dispensary"
🇷🇺Omsk, Russian Federation
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium